Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

Cancer Biology and Therapy

Volumn 10, Issue 11, 2010, Pages 1201-1214

  Wu, Xiaosong ^a   Shi, Jumei ^a   Wu, Yi ^b   Tao, Yi ^a   Hou, Jun ^a   Meng, Xiuqin ^a   Hu, Xiaojing ^a   Han, Ying ^a   Jiang, Wei ^a   Tang, Siyuan ^c   Zangari, Maurizio ^d,e   Tricot, Guido ^d,e   Zhan, Fenghuang ^d,e  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Extrinsic signaling pathway; Intrinsic signaling pathway; Myeloma; p53; TRAIL

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DIPLOIDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MITOCHONDRIAL MEMBRANE; MYELOMA; MYELOMA CELL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL CYCLE; CELL GROWTH PROCESSES; CELL SURVIVAL; DOWN-REGULATION; HUMANS; INTERFERON REGULATORY FACTOR-1; MULTIPLE MYELOMA; OXIDES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78649845794     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.11.13669     Document Type: Article

References (38)

1. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-30.
2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336:1657-64.
3. Boccadoro M, Pileri A. Diagnosis, prognosis and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997; 11:111-31. (Pubitemid 27147749)
4. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929-36. (Pubitemid 46638847)
5. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144-51.
6. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83.
7. Kalmadi SR, Hussein MA. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 2006; 116:1-7. (Pubitemid 43990951)
8. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol 2000; 27:495-501.
9. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14:262-70. (Pubitemid 30095381)
10. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present and future. Leuk Res 2004; 28:891-900.
11. 2/M cell cycle arrest, activation of caspase-8 or caspase-9 and synergy with APO2/TRAIL. Blood 2003; 101:4078-87.
12. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006; 7:192-8.
13. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-8.
14. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109:2276-84. (Pubitemid 46425864)
15. Chen YB, Fu WJ, Hou J, Ding SQ, Wang DX, et al. [Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells]. Zhonghua Xue Ye Xue Za Zhi 2003; 24:193-6.
16. Baysan A, Yel L, Gollapudi S, Su H, Gupta S. Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 2007; 30:313-8.
17. Zhou Y, Huang X, Cai X. [Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells]. Zhonghua Zhong Liu Za Zhi 2001; 23:181-3.
18. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21 and apoptosis. Cancer Res 2000; 60:3065-71.
19. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24:2899-908.
20. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569-75.
21. Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003; 38:234-9. (Pubitemid 37259640)
22. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98:2229-38.
23. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8:782-98.
24. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39:1462-75. (Pubitemid 47031030)
25. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004; 23:3051-60. (Pubitemid 39093599)
26. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, et al. Gene expression of anti- and proapoptotic proteins in malignant and normal plasma cells. Br J Haematol 2009; 145:45-58.
27. Sutherland KD, Vaillant F, Alexander WS, Wintermantel TM, Forrest NC, Holroyd SL, et al. c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J 2006; 25:5805-15. (Pubitemid 44967764)
28. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007; 12:4839-54.
29. Chau BN, Wang JY. Coordinated regulation of life and death by RB. Nat Rev Cancer 2003; 3:130-8.
30. Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem 2005; 280:12339-43.
31. Chen G, Wang Y, Huang H, Lin F, Wu D, Sun A, et al. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol 2009; 82:176-83.
32. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008; 112:2450-62.
33. Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010; 34:85-92.
34. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007; 138:467-78.
35. Mallick S, Ghosh P, Samanta SK, Kinra S, Pal BC, Gomes A, et al. A saikosaponin-like compound isolated from Corchorus acutangulus Lam., targets mitochondrial apoptotic pathways in leukemic cell lines (HL-60 and U937). Cancer Chemother Pharmacol 2009.
36. Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, et al. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J 2010; 29:2538-52.
37. Nicholson J, Hupp TR. The molecular dynamics of MDM2. Cell Cycle 2010; 12:9.
38. Kircelli F, Akay C, Gazitt Y. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. Int J Oncol 2007; 30:993-1001.